JOE
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Journal of Endocrinology (1983) 96, 107-114    DOI: 10.1677/joe.0.0960107
© 1983 Society for Endocrinology

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Spencer, G. S. G.
Right arrow Articles by Colenbrander, B.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Spencer, G. S. G.
Right arrow Articles by Colenbrander, B.

Somatomedin activity and growth hormone levels in body fluids of the fetal pig: effect of chronic hyperinsulinaemia

G. S. G. Spencer, D. J. Hill, G. J. Garssen, A. A. Macdonald and B. Colenbrander

Chronic hyperinsulinaemia in the presence of euglycaemia was obtained in pig fetuses between 90 and 104 days gestational age (term is 114 days) by the implantation of insulin-filled osmotic minipumps. At 104 days these fetuses were compared with both saline-implanted controls and with unoperated fetuses from the same sows.

Mean plasma GH levels were the same in all three treatment groups and were much greater than in the maternal peripheral venous circulation. Levels of GH in amniotic fluid were low, and even lower levels were measured in lung fluid. Glucose and protein levels were also lower in amniotic fluid than in plasma and lower still in lung fluid. In contrast, somatomedin activity was higher in amniotic and lung fluids than in fetal plasma and, when expressed relative to protein content, was highest in lung fluid. Insulin-treated fetuses had significantly (P < 0·05) higher levels of somatomedin activity than control fetuses, but despite this were neither longer nor heavier than control fetuses. From these data it is concluded that neither insulin nor somatomedin directly affect fetal growth.




This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
A. L. Ogilvy-Stuart, S. J. Hands, C. J. Adcock, J. M. P. Holly, D. R. Matthews, V. Mohamed-Ali, J. S. Yudkin, A. R. Wilkinson, and D. B. Dunger
Insulin, Insulin-Like Growth Factor I (IGF-I), IGF-Binding Protein-1, Growth Hormone, and Feeding in the Newborn
J. Clin. Endocrinol. Metab., October 1, 1998; 83(10): 3550 - 3557.
[Abstract] [Full Text]


Home page
J. Nutr.Home page
E. A. Liechty and S. C. Denne
Regulation of Fetal Amino Acid Metabolism: Substrate or Hormonal Regulation?
J. Nutr., February 1, 1998; 128(2): 342 - 342.
[Abstract] [Full Text]


Home page
J Biomater ApplHome page
M. J. Nitsch and U. V. Banakar
Implantable Drug Delivery
J Biomater Appl, January 1, 1994; 8(3): 247 - 284.
[PDF]




HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1983 by the Society for Endocrinology.